Compare Stocks: KOD, UTHR, EXEL, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$227.87 +0.2%	$249.55	$186.05 ▼ $282.15	$14.21B	0.38	700,061 shs	641,433 shs
EXEL Exelixis	$58.39 +0.8%	$55.85	$33.76 ▼ $61.14	$14.47B	0.47	2.61 million shs	1.97 million shs
KOD Kodiak Sciences	$94.45 -4.1%	$42.47	$10.94 ▼ $104.00	$5.94B	2.02	1.12 million shs	2.67 million shs
UTHR United Therapeutics	$541.70 -5.2%	$510.03	$409.07 ▼ $609.35	$23.23B	0.49	540,723 shs	1.08 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.23%	-1.47%	-12.66%	-17.19%	+11.37%
EXEL Exelixis	-0.80%	-0.02%	+1.85%	+3.74%	+40.63%
KOD Kodiak Sciences	+3.86%	+196.39%	+165.68%	+155.47%	+524.75%
UTHR United Therapeutics	+5.44%	+21.00%	+11.45%	+2.78%	+30.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$227.87 +0.2%	$249.55	$186.05 ▼ $282.15	$14.21B	0.38	700,061 shs	641,433 shs
EXEL Exelixis	$58.39 +0.8%	$55.85	$33.76 ▼ $61.14	$14.47B	0.47	2.61 million shs	1.97 million shs
KOD Kodiak Sciences	$94.45 -4.1%	$42.47	$10.94 ▼ $104.00	$5.94B	2.02	1.12 million shs	2.67 million shs
UTHR United Therapeutics	$541.70 -5.2%	$510.03	$409.07 ▼ $609.35	$23.23B	0.49	540,723 shs	1.08 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.23%	-1.47%	-12.66%	-17.19%	+11.37%
EXEL Exelixis	-0.80%	-0.02%	+1.85%	+3.74%	+40.63%
KOD Kodiak Sciences	+3.86%	+196.39%	+165.68%	+155.47%	+524.75%
UTHR United Therapeutics	+5.44%	+21.00%	+11.45%	+2.78%	+30.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	37.41% Upside
EXEL Exelixis	2.35	Hold	$50.29	-13.85% Downside
KOD Kodiak Sciences	2.63	Moderate Buy	$100.43	11.90% Upside
UTHR United Therapeutics	2.71	Moderate Buy	$621.00	13.44% Upside

Current Analyst Ratings Breakdown

Latest KOD, UTHR, EXEL, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/30/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$103.00
9/28/2026	KOD Kodiak Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$112.00
9/28/2026	KOD Kodiak Sciences	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$85.00 ➝ $145.00
9/28/2026	KOD Kodiak Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$80.00 ➝ $120.00
9/28/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $96.00
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/24/2026	UTHR United Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Sell	$321.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/24/2026	UTHR United Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Sell	$321.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.32	N/A	N/A	($2.97) per share	-76.14
EXEL Exelixis	$2.32B	6.23	$3.02 per share	19.30	$8.06 per share	7.24
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
UTHR United Therapeutics	$3.18B	7.38	$33.32 per share	16.43	$164.81 per share	3.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	17.53	25.32	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.37	15.69	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	19.60	18.46	2.72	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest KOD, UTHR, EXEL, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
KOD Kodiak Sciences	N/A	2.49	2.49
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
KOD Kodiak Sciences	89.06%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
KOD Kodiak Sciences	44.40%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

KOD, UTHR, EXEL, and ASND Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

1 hour ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Shares Down 4.1% on Insider Selling

October 2 at 10:39 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)

October 2 at 8:27 AM | theglobeandmail.com

United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares

October 2 at 5:07 AM | insidertrades.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $3,926,212.60 in Stock

October 1 at 7:07 PM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,689,085.00 in Stock

October 1 at 7:07 PM | marketbeat.com

United Therapeutics Prevails In Patent Litigation Against Liquidia

October 1 at 6:23 PM | rttnews.com

United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle

October 1 at 5:11 PM | barchart.com

Why United Therapeutics (UTHR) Stock Is Up Today

October 1 at 2:51 PM | quiverquant.comQ

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

October 1 at 1:20 PM | zacks.com

Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute

October 1 at 12:31 PM | benzinga.com

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

October 1 at 11:49 AM | benzinga.com

United Therapeutics Won Its Patent War and Liquidia Collapsed

October 1 at 11:10 AM | 247wallst.com

United Therapeutics Won Its Patent War and Liquidia Collapsed

October 1 at 11:07 AM | 247wallst.com

United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia

October 1 at 8:31 AM | benzinga.com

Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More

October 1 at 8:31 AM | 247wallst.com

United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia

October 1 at 8:14 AM | benzinga.com

United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

October 1 at 8:05 AM | zacks.com

Liquidia (LQDA) Stock Crashes 57% After Court Ruling Favors United Therapeutics

October 1 at 7:46 AM | coincentral.comC

United Therapeutics wins Yutrepia patent ruling

October 1 at 7:46 AM | grafa.comG

United Therapeutics (UTHR) Stock Jumps 13% After Crushing Court Win Over Rival

October 1 at 7:46 AM | coincentral.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KOD, UTHR, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$227.87 +0.56 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$228.00 +0.13 (+0.06%)

As of 04:15 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$58.39 +0.45 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$58.40 +0.01 (+0.02%)

As of 05:07 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Kodiak Sciences NASDAQ:KOD

$94.45 -4.01 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$94.20 -0.26 (-0.27%)

As of 06:41 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

United Therapeutics NASDAQ:UTHR

$541.70 -29.68 (-5.19%)

Closing price 04:00 PM Eastern

Extended Trading

$538.36 -3.35 (-0.62%)

As of 06:38 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, UTHR, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, UTHR, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, UTHR, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, UTHR, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Kodiak Sciences NASDAQ:KOD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, UTHR, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, UTHR, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, UTHR, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, UTHR, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Kodiak Sciences NASDAQ:KOD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools